Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Ladenburg Thalmann Financial Services Inc. Increases Position in Editas Medicine Inc (NASDAQ:EDIT)
09:36am, Sunday, 12'th Apr 2020
Ladenburg Thalmann Financial Services Inc. grew its holdings in Editas Medicine Inc (NASDAQ:EDIT) by 11.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1
Head-To-Head Comparison: Rubius Therapeutics (NASDAQ:RUBY) versus Editas Medicine (NASDAQ:EDIT)
05:16am, Sunday, 12'th Apr 2020
Rubius Therapeutics (NASDAQ:RUBY) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of the
Editas Medicine Inc (NASDAQ:EDIT) Given Consensus Rating of "Hold" by Analysts
05:58am, Tuesday, 07'th Apr 2020
Editas Medicine Inc (NASDAQ:EDIT) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One research ana
Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?
12:59pm, Monday, 06'th Apr 2020
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?
12:59pm, Monday, 06'th Apr 2020
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Is CRISPR Therapeutics Stock a Buy?
12:07pm, Sunday, 05'th Apr 2020
What should investors think of this well-known gene-editing company?
Captrust Financial Advisors Grows Stock Holdings in Editas Medicine Inc (NASDAQ:EDIT)
09:34am, Thursday, 02'nd Apr 2020
Captrust Financial Advisors increased its stake in shares of Editas Medicine Inc (NASDAQ:EDIT) by 7,925.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Co
Better Buy: Editas Medicine vs Sangamo Therapeutics
01:31pm, Wednesday, 01'st Apr 2020
Which of these two gene-editing companies is the better investment?
Modalis Obtains Access to Foundational CRISPR IP
04:00am, Wednesday, 01'st Apr 2020
Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intel
Amalgamated Bank Boosts Stake in Editas Medicine Inc (NASDAQ:EDIT)
08:34am, Tuesday, 31'st Mar 2020
Amalgamated Bank boosted its stake in shares of Editas Medicine Inc (NASDAQ:EDIT) by 8.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Excha
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
03:31pm, Friday, 27'th Mar 2020
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
03:31pm, Friday, 27'th Mar 2020
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If You Had Bought Editas Medicine (NASDAQ:EDIT) Stock A Year Ago, You’d Be Sitting On A 12% Loss, Today
12:30pm, Thursday, 26'th Mar 2020
You can invest in an index fund if you want to make sure your returns approximately match the overall market. In...
Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
02:02pm, Wednesday, 25'th Mar 2020
Sangamo has announced several impressive partnerships with global biotech and big pharma companies. Its recent deal with Biogen gives it ~$700M cash on hand, at
$5.95 Million in Sales Expected for Editas Medicine Inc (NASDAQ:EDIT) This Quarter
09:02am, Monday, 23'rd Mar 2020
Brokerages expect that Editas Medicine Inc (NASDAQ:EDIT) will announce $5.95 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Editas Medicine’s earni
